Arsenio is an IDEAL Council member and a clinical trials methodologist with a particular interest in study design and clinical trials methods in complex interventions. His DPhil research at Oxford in intervention fidelity in clinical trials was greatly inspired by the IDEAL framework.
Arsenio’s clinical background is in CNV genetic, neurodevelopmental and neurodegenerative disorders. He is particularly interested in how IDEAL can be applied to trials that combine surgery, medical devices and biologics, such as advanced therapy medicinal products (ATMPs) in regenerative medicine and rehabilitation trials. He is also keenly interested in applying IDEAL to sleep medicine and behavioural neuroscience clinical trials.
Arsenio lead the working group considering when RCTs are, or are not, appropriate for implantable medical devices, and what other study designs or forms of evidence are appropriate instead.
He also lead a real world data working group, and is one of IDEAL’s clinical specialty leads. As a development lead at IDEAL, he is excited to support the development of a North American IDEAL centre and foster greater collaboration between IDEAL centres in the UK, Europe, and Asia.
Arsenio also co-leads a multi-centre working group working to adapt the IDEAL framework to accommodate surgical regenerative medicine trials.